CSL Limited
- Exclusive
- Coronavirus pandemic
How the Morrison government passed over an Australian company for a US pharmaceutical giant
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up vaccine manufacturing in Australia.
- Paul Sakkal and Liam Mannix
Latest
- Exclusive
- Funding
The hundreds of millions in tax incentives for Australian start-ups that went south
The R&D tax offset has served as a life raft for some of Australia’s most prominent technology start-ups, though in some cases it wasn’t enough.
- David Swan
- Updated
- World markets
ASX slides despite Wall Street rebound
Rate-sensitive sectors including consumer stocks dragged the local sharemarket lower, despite a US equities rebound overnight following its steep sell-off.
- Millie Muroi
Failed drug trial overshadows CSL’s bumper profits
Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.
- David Swan
Health behemoth CSL sheds $7b in value after heart drug fails trial
Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.
- Millie Muroi
- Analysis
- Active investing
Nine stock picks from some of Australia’s biggest fund managers
From garbage collection to race car manufacturing, nine fund managers at some of Australia’s largest investment firms have given their best stock picks.
It’s throwing its weight around, but can Ozempic reshape our economy?
From health to fast food, investors are starting to question which companies will be slimmed thanks to weight-loss drugs.
- Emma Koehn and Colin Kruger
Our biggest healthcare company says it isn’t scared of Ozempic
CSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
- Emma Koehn
‘Every reason to be grumpy’: CSL defends share price to investors
Shareholders have grilled the biotech giant about its long-term strategy as the stock sits close to 10 per cent lower for the year.
- Emma Koehn
CSL aims to get better bang for buck from plasma
The ASX heavyweight and the nation’s largest healthcare company is looking to make its operations more efficient to counter inflation and currency woes.
- Emma Koehn
Original URL: https://www.brisbanetimes.com.au/topic/csl-g9